HHS seeks input on how the federal government classifies vaccine recommendations, including whether its current system gives patients and parents enough choice.
FDA extends by three months its review of a Capricor Therapeutics BLA for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD).
HHS seeks input on how the federal government classifies vaccine recommendations, including whether its current system gives patients and parents enough choice.
FDA extends by three months its review of a Capricor Therapeutics BLA for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy (DMD).
As Amgen continues its bid to prevent the withdrawal of Tavneos (avacopan) in the U.S., a new study finds that while liver enzyme elevations were uncommon among patients treated with avacopan, although two cases of drug-induced liver injury were identified.
FDA issues an early alert about a potentially high-risk problem involving certain CooperSurgical INCA neonatal and infant nasal continuous positive airway pressure sets.
